Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the Dr Mike Owen has stepped down from his role as Non-executive Director of the Avacta Group plc Board, a position which he has held since 2015, with effect from 24 March 2021.
Mike will continue with Avacta Group, in the non-Board role of Chair of the Scientific Advisory Board.
Dr Eliot Forster, Chairman of Avacta Group commented:
"We are grateful for Mike many years of invaluable contribution to the Board of Directors, bringing his incomparable experience and expertise to the company. Mike is one of the industry's outstanding leaders and Avacta has been lucky to benefit from his contributions. I very much look forward to continuing to work with Mike in his role as Chair of the Scientific Advisory Board."
Dr Alastair Smith, Chief Executive of Avacta Group commented:
"Avacta has benefited hugely from Mike's scientific and commercial input at the Board and I am very pleased that we will be able to continue to draw upon Mike's vast therapeutics experience in his role as Chair of the Scientific Advisory Group.
I would like to add my personal thanks to Mike for his support and advice over the years which has been invaluable to me."
That didn’t sound right Monk,
From the NHS guidelines,
Lateral flow device – storage and box contents
Space will need to be made available for storage of devices at between 40C and 300C. The testing kits will arrive in boxes. The dimensions of each box are: 7 by 4.5 by 5.5 inches.
Each box contains the following:
• 25 foil pouches containing the test cartridge and a desiccant
• two vials of 6 mls buffer solution
• 25 extraction tubes and 25 tube caps
• 25 sterilised swabs for nasal sample collection
• manufacturer instructions for use of the device (IFU).
Who are GAD manufacturing for? Up to £1Bhttps://bidstats.uk/tenders/2021/W11/747045154
https://bidstats.uk/tenders/2021/W11/747045154
GAD up to £1B
3. Details of person subject to the notification obligationiv
Name
Richard Griffiths and controlled undertakings
City and country of registered office (if applicable)
St Helier, Jersey
4. Full name of shareholder(s) (if different from 3)v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi:
2 February 2021
6. Date on which issuer notified (DD/MM/YYYY):
4 February 2021
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached
3.30%
1.91%
5.21%
131,498,555
Position of previous notification (if
applicable)
3.05%
1.04%
4.09%
Amended NI 43-101 Technical Report on the
Cascabel Property, Alpala Deposit, Northern Ecuador
The Board of SolGold (LSE and TSX code: SOLG) is pleased to announce the filing on SEDAR of an amended and restated independent NI 43-101 Technical Report entitled:
"Cascabel Property NI 43-101 Technical Report, Alpala Porphyry Copper-Gold-Silver Deposit - Mineral Resource Estimation, January 2021" with an Effective date: 18 March 2020" and Amended Date: 7 January 2021 (the Technical Report).
This amended Technical Report has been relodged to recognise SolGold Plc ("the Company") and Cornerstone Capital Resources Inc. ("Cornerstone") as common issuers of the current Technical Report on the Cascabel Property, Alpala Porphyry Copper-Gold-Silver Deposit - Mineral Resource Estimation.
The amended Technical Report does not change the mineral resources, or any other technical content outlined in the original report dated 22 May 2020 or the amended report dated 29 September 2020, other than readdressing and re-dating the report.
Gamma Biosciences’ bioseparation business Astrea will use the Affimer technology to expand its range of ligand discovery and development capabilities.
Avacta Group’s Affimer reagents are small proteins that have a binding surface that can be tailored to capture a target molecule of interest out of complex mixtures encountered in biomanufacturing.
“The Affimer reagent technology was originally developed at the MRC Cancer Unit in Cambridge UK for proteomics applications and was acquired by Avacta in 2012,” Alastair Smith, CEO of Avacta Group, told BioProcess Insider. “Avacta has since developed the Affimer technology into a robust platform with diverse applications in diagnostics, therapeutics and other fields such as affinity separation.”
He added key competitive advantages of Affimer reagents are “their high degree of specificity to the target of interest, their robustness and adaptability, and their low cost of manufacture.
“Affimer reagents can be generated quickly, in a matter of a few weeks, to bind a new target with high affinity and specificity and can then be attached to the affinity separation resin using straightforward chemistry. Unlike most proteinaceous binding reagents, Affimer molecules can withstand the harsh cleaning conditions required to re-use the bioseparation columns many times.”
I n Avacta’s latest licensing deal, Astrea Bioseparations – formerly Prometic Bioseparations – will use the Affimer tech as an alternative and complementary ligand platform that to broaden the scope of its ligand discovery/adsorbent development offerings.
“The agreement with Avacta means Astrea is now able to offer affinity adsorbent development services with a very high probability of success,” said Astrea CEO Steve Burton.
“When combined with Astrea’s existing and very significant, high quality adsorbent manufacturing capacity and the company’s ability to supply the final product in bulk, in nanofibre membrane format or in pre-packed GMP-ready columns, the deal with Avacta confirms Astrea’s position as a leading developer, manufacturer and supplier of high quality, high performance affinity adsorbents.”
Financial details of the deal have not been disclosed, but support came from Astrea’s owners Gamma, which also provided strategic and legal support on the transaction.
Note: other technologies that have been validated will be added to the table once the manufacturer has consented to publication.
Lateral Flow Test Kits
A Contract Award Notice
by DEPARTMENT OF HEALTH AND SOCIAL CARE
Source
Contracts Finder
Type
Contract (Products)
Duration
8.5 month
Value
£75M
Sector
HEALTH
Published
11 Dec 2020
Delivery
02 Jun 2020 to 14 Feb 2021
Deadline
02 Jun 2020 00:00
Concepts
provision of lateral flow test kits
lateral flow test kits
diagnostics and radiodiagnostics
part of the uk covid-19 testing strategy
antibody testing
devices and supplies
use
support of pillar
covid-19
https://bidstats.uk/tenders/2020/W50/740688122